Edwards to roll out Physio II
This article was originally published in The Gray Sheet
Executive SummaryEdwards Lifesciences will launch its Carpetier-Edwards Phyiso II mitral valve annuloplasty repair ring in the U.S. and Europe in the first quarter of 2009, and expects it to help drive a 15% revenue boost in its heart valve therapy division to nearly $670 million in 2009, the company announces during its Feb. 3 fourth-quarter earnings call. FDA recently cleared Physio II via 510(k) and the device also has CE mark approval. Physio II is the only annuloplasty ring to offer "shape optimization" that matches the shape of the ring to the shape of the patient's diseased valve, according to Edwards. It also features a unique sewing cuff, making it easier for surgeons to implant, according to the company
You may also be interested in...
Having had a very fruitful year in terms of regulatory approvals, the Swiss major will reveal how successful its new products have been commercially. Of particular interest will be the performance of eye drug Beovu as it takes on Bayer's rival Eylea.
Executives On The Move: New Picks For Finance Posts At Cambrex And Editas Medicine, And Zimmer Biomet Fills Communications Spot
Gene-editing company Editas Medicine appoints a new CFO, while Affimed and NexImmune bring new chief medical officers on board.
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.